EMA Fells Two Orphan Drugs, Delays Teva’s Nerventra
This article was originally published in The Pink Sheet Daily
Executive Summary
The CHMP rejects AB Science’s Masiviera for pancreatic cancer, PTC Therapeutics’ Translarna for Duchenne muscular dystrophy and Teva’s Nerventra for MS.